Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
FENNEC PHARMACEUTICALS director Rosty Raykov exercised stock options and sold shares in a largely pre-planned, tax-related transaction. On April 1, 2026, he exercised 15,598 stock options at $2.45 per share, acquiring the same number of common shares under a Rule 10b5-1 trading plan adopted on September 19, 2025. On the same date, he sold 10,946 common shares at $6.31 per share to satisfy tax obligations related to the option exercise, also under that plan. A day earlier, on March 31, 2026, he received 5,208 common shares as a grant released from prior restricted awards. After these trades, he directly owned 113,856 common shares, indicating he retained most of the exercised shares.
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported equity compensation activity. On March 31, 2026, he received incentive stock options for 120,000 common shares at $5.77 per share, expiring March 31, 2036, under the 2020 Equity Incentive Plan.
One-third of these options vest on March 31, 2027, with additional vesting monthly until fully vested by March 31, 2029. The filing also shows settlement of performance share units and release of restricted shares, bringing direct holdings to 20,679 common shares. All transactions reflect awards and vesting rather than open‑market trading.
Andrade Robert reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. reported insider equity awards for Chief Financial Officer Robert Andrade. On March 31, 2026, he received incentive stock options to purchase 120,000 common shares at $5.77 per share under the 2020 Equity Incentive Plan, vesting monthly from March 31, 2027 until March 31, 2029.
On the same date, 14,724 common shares were issued from settlement of PSUs that vested, and 2,213 common shares were released from restriction from prior awards. On March 28, 2026, 12,270 additional common shares were released from restriction from a 2025 award. Following these transactions, he directly holds 273,593 common shares and 921,045 stock options.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L Evans received an incentive stock option grant covering 120,000 common shares at an exercise price of $5.77 per share. The options were granted under the 2020 Equity Incentive Plan and vest over time, with one-third exercisable as of March 31, 2027 and the remainder vesting monthly so that all are vested by March 31, 2029.
On the same date, Evans also acquired common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025. Following these equity awards and releases, Evans directly holds 20,679 common shares and 270,000 stock options, reflecting routine compensation-related transactions rather than open-market buying or selling.
The filing notifies sales of 10,946 shares of Common Stock via a stock option exercise reported as an issuer transaction on 04/01/2026. It also lists three reported open-market dispositions in the prior three months: 10,079 shares for $84,354.17, 10,349 shares for $80,339.29, and 10,312 shares for $78,471.23.
Fennec Pharmaceuticals is a commercial-stage specialty pharma company focused on preventing cisplatin-induced hearing loss with its drug PEDMARK in the U.S. and PEDMARQSI in Europe and other regions. The product is FDA- and European Commission-approved for pediatric patients with localized, non-metastatic solid tumors and showed about a 50% relative reduction in hearing loss versus cisplatin alone in clinical studies.
In March 2024, Fennec signed an exclusive licensing deal with Norgine, receiving about $43 million upfront, with up to about $230 million in potential milestones and double-digit tiered royalties on PEDMARQSI net sales. Norgine launched PEDMARQSI in Germany and the U.K. in 2025, with further European launches expected. Fennec also added a 2025 distribution agreement with Inpharmus for Turkey and Gulf Cooperation Council countries and reported positive 2025 Japanese STS-J01 trial results, supporting a registration strategy and potential partnering there.
The company has U.S. Orphan Drug Exclusivity for PEDMARK until September 20, 2029 and European pediatric-use marketing exclusivity until May 26, 2033, alongside a broad patent estate expiring around 2039. In March 2026, Fennec settled litigation with Cipla over a proposed generic, with Cipla agreeing not to launch its sodium thiosulfate product before September 1, 2033, reinforcing PEDMARK’s commercial runway.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.
Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.
Fennec Pharmaceuticals reported strong growth in its core PEDMARK product but a wider loss for 2025. Net product sales reached $44.6 million for the year, up 50% from 2024, with Q4 2025 net product sales of $13.8 million, 75% above Q4 2024. Total 2025 revenue was $44.6 million versus $47.5 million in 2024, which had included one-time licensing revenue. Operating expenses rose to $51.4 million, leading to a full-year net loss of $10.1 million compared with a $0.4 million net loss in 2024. Cash and cash equivalents increased to $36.8 million as of December 31, 2025, and all term-loan debt was eliminated, helping turn shareholders’ equity from a deficit to a positive $35.1 million. The company highlighted record patient enrollments and an oversubscribed $42 million equity raise, along with positive clinical data supporting PEDMARK’s use in additional settings.
Fennec Pharmaceuticals Inc. reported that it has entered into a License Agreement with Cipla Limited and Cipla USA, Inc. to settle litigation over Cipla’s bid to market a generic version of Fennec’s PEDMARK® sodium thiosulfate injection. The lawsuit will be dismissed, with each party bearing its own costs. Cipla has agreed not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances. PEDMARK, Fennec’s FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in certain pediatric cancer patients, remains the only approved product of its kind and is protected by orphan drug exclusivity and patents the company states extend to 2039.